|
Variablea
|
Young group (16–64 years old, n = 9122)
|
Elderly group (65–74 years old, n = 7155)
|
Older elderly group (over 75 years old, n = 6419)
|
|---|
|
Median age [IQR]
|
54 [45, 60]
|
70 [67, 72]
|
79 [77, 83]
|
|
Sex, female, %
|
75.3
|
69.6
|
72.9
|
|
Median observation period, months [IQR]
|
26 [13, 36]
|
24 [13, 36]
|
19 [10,34]
|
|
Median Charlson Comorbidity Index score [IQR]
|
1 [1, 2]
|
2 [1,3]
|
2 [1,3]
|
|
Comorbidity, %
|
|
Chronic pulmonary disease
|
12.4
|
16.2
|
17.2
|
|
Renal disease
|
1.8
|
3.5
|
4.9
|
|
Diabetes mellitus
|
6.1
|
11.4
|
11.0
|
|
History of HI
|
2.8
|
4.1
|
6.1
|
|
Medication use for RA, %
|
|
MTX
|
83.0
|
82.3
|
76.9
|
|
bDMARDs
|
34.1
|
29.3
|
29.8
|
|
TNF inhibitor
|
22.3
|
15.6
|
14.5
|
|
Infliximab
|
4.0
|
1.6
|
0.6
|
|
Etanercept
|
6.6
|
5.2
|
5.3
|
|
Adalimumab
|
5.7
|
2.4
|
1.6
|
|
Golimumab
|
4.3
|
5.5
|
6.6
|
|
Certolizumab pegol
|
1.7
|
1.0
|
0.5
|
|
Tocilizumab
|
7.9
|
5.7
|
4.4
|
|
Abatacept
|
3.9
|
8.0
|
10.9
|
|
JAKIs
|
1.3
|
1.7
|
1.5
|
|
Tofacitinib
|
0.8
|
1.0
|
1.1
|
|
Baricitinib
|
0.5
|
0.7
|
0.4
|
|
Oral CS
|
43.5
|
47.8
|
55.5
|
|
Median dose of oral CS, mg/day [IQR]b
|
5 [4, 10]
|
5 [4, 7.5]
|
5 [4, 7.5]
|
- bDMARDs Biological disease-modifying antirheumatic drugs, CS Corticosteroids, HI Hospitalized infection, IQR Interquartile range, JAKIs Janus kinase inhibitors, MTX Methotrexate, RA Rheumatoid arthritis, TNF Tumor necrosis factor
- aComorbidity and history of hospitalized infection were defined a year before the index month. Other variables were defined in the index month
- bDoses of oral corticosteroids were converted to prednisolone equivalent doses
